Thus, availability of K5+/K19+ and K5+/K19− mammary stem/progenitor cell lines generated in our laboratory provides a unique opportunity to assess their ability to serve as cells of origin for breast tumors and the impact of cell type versus oncogenes in tumor associated characteristics. The gene discussed is KRT19; the disease is neoplasm.